Avastin plus Chemotherapy versus Avastin plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Platinum-Resistant or –Sensitive Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer (ACSCO trial)

About this Study

The purpose of this study is to screen chemotherapy drugs currently used for the care of recurrent ovarian cancer and to determine the most effective treatment based on results from a chemosensitivity assay.

Sponsor Protocol ID:ChemoID
IRB Number:2018-0147
Closed for Enrollment
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Informed consent obtained and signed. 
  • Willing and able to commit to study procedures including long-term follow-up visit(s). 
  • At least 18 years old at the time of enrollment. 

Exclusion Criteria
  • Previously participated in this study. 
  • Any condition that would, in the opinion of the investigator, place the participant at an 20 unacceptable risk, or render the participant unable to meet the requirements of the protocol
    (including long-term study follow-up). 
  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments.

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Wilkinson, Kelly J, M.D.
How to participate in our Clinical Trials